Details

Autor(en) / Beteiligte

• Louie, Thomas J
• Miller, Mark A
• Mullane, Kathleen M
• Weiss, Karl
• Lentnek, Arnold
• Golan, Yoav
• Gorbach, Sherwood
• Sears, Pamela
• Shue, Youe-Kong

Titel

Fidaxomicin versus Vancomycin for Clostridium difficile Infection

Ist Teil von

• The New England journal of medicine, 2011-02, Vol.364 (5), p.422-431

Ort / Verlag

Waltham, MA: Massachusetts Medical Society

Erscheinungsjahr

2011

Link zum Volltext

Quelle

Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals

Beschreibungen/Notizen

• In this randomized trial of fidaxomicin as compared with vancomycin in 629 patients, oral fidaxomicin was shown to be noninferior to oral vancomycin in the treatment of C. difficile infection and was associated with lower rates of recurrence. Clostridium difficile infection generally occurs after exposure to broad-spectrum antibiotics. The incidence and severity of C. difficile infection are increasing. The increases have been ascribed to the emergence of a hypervirulent C. difficile strain, known variously as North American Pulsed Field type 1 (NAP1), restriction-endonuclease analysis (REA) type BI, or polymerase-chain-reaction ribotype 027 (referred to collectively as the NAP1/BI/027 strain). 1 – 4 Furthermore, the rates of death associated with C. difficile infection are rising, 5 – 7 and the infection is occurring in populations that were previously considered to be at low risk, such as young, healthy persons living in the community and . . .